Evolve Private Wealth LLC acquired a new position in Repligen Corporation (NASDAQ:RGEN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,801 shares of the biotechnology company’s stock, valued at approximately $519,000.
Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC purchased a new position in Repligen in the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP purchased a new position in Repligen in the 4th quarter worth approximately $2,399,209,000. Wasatch Advisors LP boosted its stake in Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after purchasing an additional 346,720 shares during the period. Finally, Maverick Capital Ltd. purchased a new stake in Repligen during the 1st quarter valued at approximately $178,946,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Wall Street Analysts Forecast Growth
RGEN has been the topic of several recent analyst reports. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Repligen has an average rating of “Buy” and a consensus price target of $166.43.
Repligen Trading Up 0.3%
RGEN stock opened at $181.62 on Tuesday. The firm has a fifty day moving average price of $148.17 and a 200 day moving average price of $131.97. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73. The firm has a market cap of $10.25 billion, a PE ratio of 248.79, a price-to-earnings-growth ratio of 3.31 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05.
Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the business earned $0.26 earnings per share. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.
Insider Activity at Repligen
In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.
Repligen Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Read More
- Five stocks we like better than Repligen
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
